IFI16 mis-localization can be a contributing factor to hepatocellular carcinoma progression

Area of Science:

• Hepatobiliary cancers
• Molecular oncology
• Cancer epigenetics

Background:

• Hepatocellular carcinoma (HCC) presents significant drug resistance, with underlying mechanisms poorly understood.
• Interferon-γ inducible protein 16 (IFI16) is a multifunctional protein involved in cell regulation and immunity, typically absent in healthy adult hepatocytes but present in liver cancer cells.
• Dysregulation of IFI16 is implicated in HCC drug resistance and tumor progression, with its function dependent on subcellular localization.

Purpose of the Study:

• To investigate the subcellular localization of IFI16 in HCC cells.
• To determine if IFI16 exhibits chromatin-binding properties in HCC.
• To explore the potential association between IFI16 chromatin localization and HCC progression.

Main Methods:

• Analysis of IFI16 localization in four HCC cell lines with varying TP53 genotypes.
• Comparison of IFI16 localization in HCC cells versus a fetal liver cell line (L02).
• Assessment of IFI16 as a chromatin-binding protein.

Main Results:

• IFI16 was identified as a chromatin-binding protein in all tested HCC cell lines.
• IFI16 did not exhibit chromatin-binding properties in the L02 fetal liver cell line.
• This study provides the first evidence of IFI16 chromatin binding in HCC.

Conclusions:

• Chromatin localization of IFI16 is demonstrated in HCC cells.
• IFI16 chromatin binding is presumed to be associated with HCC progression.
• Targeting IFI16 nuclear localization, potentially through acetylation or NLS deletion alongside p53 restoration, could represent a novel therapeutic strategy for HCC.